You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
舒泰神(300204.SZ):STSA-1002注射液治療重型COVID-19適應症在美獲批臨牀
格隆匯 07-19 16:31

格隆匯7月19日丨舒泰神(300204.SZ)宣佈,近日,公司收到美國食品藥品監督管理局(FDA)的通知郵件,同意STSA-1002注射液針對治療重型COVID-19適應症開展臨牀試驗。

STSA-1002注射液是以C5a為靶點的重組抗人C5aIgG1全人源單克隆抗體,通過特異性結合過敏毒素C5a,使C5a喪失結合受體的能力,阻斷C5a誘導的生物學功能,如中性粒細胞趨化、脱顆粒和氧呼吸爆發等,同時不影響C5裂解及膜攻擊複合物(MAC)的形成,保留補體系統的溶菌、殺菌功能。

近年來隨着基礎研究的不斷深入,補體系統在多種重大疾病中的作用越來越受到重視和肯定。C5a是補體系統中的“明星分子”,針對C5a靶點開發的多種治療性藥物正在不同的疾病領域展開探索性研究。德國InflaRx公司的藥物IFX-1和舒泰神及其子公司開發的BDB-001均是抗人C5a高親和力IgG4單克隆抗體,這兩種藥物與STSA-1002具有相同的治療靶點。InflaRx正在開展IFX-1用於治療化膿性汗腺炎(HS)、ANCA相關性血管炎(AAV)等5項適應症的臨牀試驗。BDB-001注射液正在開展治療化膿性汗腺炎(HS)等2項適應症的臨牀試驗,ANCA相關性血管炎(AAV)適應症的新藥臨牀試驗申請已提交併受理。

STSA-1002注射液由公司自主研發,發明專利已在國內和國際進行申請。該次新藥臨牀試驗申請是STSA-1002注射液在全球的首次臨牀試驗申請。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account